Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.8 USD | -0.39% | -1.32% | +18.02% |
02:36pm | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
May. 13 | Merck: phase 3 trial in melanoma halted | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.02% | 327B | |
+30.75% | 682B | |
+30.35% | 586B | |
-3.57% | 364B | |
+3.71% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.95% | 165B | |
-1.68% | 161B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Guggenheim Adjusts Price Target on Merck to $146 From $144